Surgical Outcomes and Recurrence Management in Borderline Resectable Hepatocellular Carcinoma: Implications for Multidisciplinary Strategies

ABSTRACT Background Oncological resectability classification for hepatocellular carcinoma (HCC) emphasizes the need to reassess treatment strategies for borderline resectable (BR) cases. This study evaluated surgical outcomes and prognostic factors in BR‐HCC and reconsidered multidisciplinary approaches for recurrence management. Methods The study comprised 433 patients who underwent primary hepatic resection for HCC between 2000 and 2023. Patients were classified as R, BR1, and BR2 according to the Expert Consensus Statement 2023. Multivariate Cox proportional hazard models were conducted to identify prognostic factors for disease‐free and overall survival in BR (BR1 + BR2) patients. Results Among 70 patients with BR‐HCC (BR1: n = 37, BR2: n = 33), 5‐year overall survival was 53% in BR1 versus 22% in BR2 patients ( p = 0.06). In multivariate analysis, up‐to‐7 out ( p < 0.001) and lymph node metastasis ( p < 0.001) were independent predictors of cancer recurrence, whereas anatomical resection was associated with improved disease‐free survival ( p = 0.02). Independent predictors of overall survival included older age ( p = 0.01), Child‐Pugh B ( p < 0.001), up‐to‐7 out ( p = 0.01), macrovascular invasion ( p = 0.01), and lymph node metastasis ( p < 0.001). Recurrence occurred in 89% of BR‐HCC patients, with BR2 showing more frequent early recurrence within 1 year ( p = 0.006) and recurrence beyond Milan criteria ( p = 0.02) compared to BR1. Patients receiving surgical resection or radiofrequency ablation for recurrence demonstrated better survival compared with other treatments ( p < 0.001). Conclusions BR1 and BR2‐HCC represent biologically aggressive subsets with high recurrence rates and poor prognosis, particularly in tumors with up‐to‐7 out status, lymph node metastasis, and macrovascular invasion. Active salvage treatment for recurrence may improve survival, highlighting the importance of multidisciplinary approaches in BR‐HCC management.

Authors

Institutions

Publication Details

Journal
Annals of Gastroenterological Surgery
Published
2026-01-20
DOI
https://doi.org/10.1002/ags3.70177
Primary Topic
Hepatocellular Carcinoma Treatment and Prognosis
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Surgical Outcomes and Recurrence Management in Borderline Resectable Hepatocellular Carcinoma: Implications for Multidisciplinary Strategies

Yuto Yamahata, Tomohiko Taniai, Koichiro Haruki, Michinori Matsumoto et al.
Annals of Gastroenterological Surgery
Hepatocellular Carcinoma Treatment and Prognosis
article

Surgical Outcomes and Recurrence Management in Borderline Resectable Hepatocellular Carcinoma: Implications for Multidisciplinary Strategies

Yuto Yamahata, Tomohiko Taniai, Koichiro Haruki, Michinori Matsumoto, Masashi Tsunematsu, Munetoshi Akaoka, Yoshihiro Shirai, 池上 徹, Shinji Onda, Kenei Furukawa
article en

Abstract

ABSTRACT Background Oncological resectability classification for hepatocellular carcinoma (HCC) emphasizes the need to reassess treatment strategies for borderline resectable (BR) cases. This study evaluated surgical outcomes and prognostic factors in BR‐HCC and reconsidered multidisciplinary approaches for recurrence management. Methods The study comprised 433 patients who underwent primary hepatic resection for HCC between 2000 and 2023. Patients were classified as R, BR1, and BR2 according to the Expert Consensus Statement 2023. Multivariate Cox proportional hazard models were conducted to identify prognostic factors for disease‐free and overall survival in BR (BR1 + BR2) patients. Results Among 70 patients with BR‐HCC (BR1: n = 37, BR2: n = 33), 5‐year overall survival was 53% in BR1 versus 22% in BR2 patients ( p = 0.06). In multivariate analysis, up‐to‐7 out ( p < 0.001) and lymph node metastasis ( p < 0.001) were independent predictors of cancer recurrence, whereas anatomical resection was associated with improved disease‐free survival ( p = 0.02). Independent predictors of overall survival included older age ( p = 0.01), Child‐Pugh B ( p < 0.001), up‐to‐7 out ( p = 0.01), macrovascular invasion ( p = 0.01), and lymph node metastasis ( p < 0.001). Recurrence occurred in 89% of BR‐HCC patients, with BR2 showing more frequent early recurrence within 1 year ( p = 0.006) and recurrence beyond Milan criteria ( p = 0.02) compared to BR1. Patients receiving surgical resection or radiofrequency ablation for recurrence demonstrated better survival compared with other treatments ( p < 0.001). Conclusions BR1 and BR2‐HCC represent biologically aggressive subsets with high recurrence rates and poor prognosis, particularly in tumors with up‐to‐7 out status, lymph node metastasis, and macrovascular invasion. Active salvage treatment for recurrence may improve survival, highlighting the importance of multidisciplinary approaches in BR‐HCC management.

Annals of Gastroenterological Surgery
Jikei University School of Medicine (JP)
Japan Society for the Promotion of Science
Good health and well-being
Openalex Percentile: Top 82%
Hepatocellular Carcinoma Treatment and Prognosis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.